Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies
Open accessAbstract
Alzheimer’s Disease (AD) is a neurodegenerative disorder related with the increase of age and it is the main cause of dementia in the world. AD affects cognitive functions, such as memory, with an intensity that leads to several functional losses. The continuous increase of AD incidence demands for an urgent development of effective therapeutic strategies. Despite the extensive research on this disease, only a few drugs able to delay the progression of the disease are currently available. In the last years, several compounds with pharmacological activities isolated from plants, animals and microorganisms, revealed to have beneficial effects for the treatment of AD, targeting different pathological mechanisms. Thus, a wide range of natural compounds may play a relevant role in the prevention of AD and have proven to be efficient in different preclinical and clinical studies. This work aims to review the natural compounds that until this date were described as having significant benefits for this neurological disease, focusing on studies that present clinical trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plant extracts may serve as valuable adjuncts or alternatives to conventional pharmacological treatments for Alzheimer's disease.
“The diverse mechanisms through which these plant extracts exert their effects—ranging from ChE inhibition to antioxidant activity—suggested that they may serve as valuable adjuncts or alternatives to conventional pharmacological treatments for AD [103,104].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 360 · Cited by 240
Research works printed but not linked: 1
- [161]Kadakkuzha B.M. Liu X.-A. Swarnkar S. Chen Y. Chapter 18—Genomic and Proteomic Mechanisms and Models in Toxicity and Safety Evaluation of Nutraceuticals Nutraceuticals Gupta R.C. Academic Press Boston, MA, USA 2016 227 237
- Authors
- Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C.
- Affiliations
- LEPABE, Department of Chemical Engineering, Faculty of Engineering of the University of Porto, 4200-465 Porto, Portugal
- Universidade do Porto (PT)
- Corresponding author
- Loureiro, Joana Angélica
- Pereira, Maria do Carmo
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-05-10
- Volume
- 20
- Issue
- 9
- Pages
- 2313
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6539304
- OpenAlex
- W2944150075
- Cited by
- 240
- References
- 360
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 38 · 2023: 42 · 2022: 35 · 2021: 43 · 2020: 36 · 2019: 6 · 2018: 1
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- FCT/MCTES (PIDDAC) (UID/EQU/00511/2019 - Laboratory for Process Engineering, Environment, Biotechnology and Energy – LEPABE)
- FEDER funds through COMPETE2020 - Programa Operacional Competitividade e Internacionalização (POCI) and by national funds (PIDDAC) through FCT/MCTES (Project POCI-01-0145-FEDER-006939)
- Norte Portugal Regional Operational Programme (NORTE 2020), under PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) (Project “LEPABE-2-ECO-INNOVATION” – NORTE‐01‐0145‐FEDER‐000005)
- Fundação para a Ciência e a Tecnologia (SFRH/BD/129312/2017)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, natural compounds, phytochemicals, animal-derived compounds, microbial metabolites, neurodegeneration, dementia, memory impairment, Alzheimer's disease prevention, therapeutic target, clinical trials
- MeSH terms
- Drug Development, Alzheimer Disease, Animals, Biological Products, Clinical Trials as Topic, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
